Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 9/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694594 | 0.81 | CRBN (0.51) | CRBNDDB1 | |
| SCHEMBL4394598 | 0.73 | CRBN (0.66) | CRBNDDB1 | |
| SCHEMBL6696508 | 0.70 | CRBN (0.48) | CRBNDDB1 | |
| SCHEMBL4398954 | 0.70 | CRBN (0.60) | CRBNDDB1 | |
| SCHEMBL6696684 | 0.70 | CRBN (0.47) | CRBNDDB1 | |
| SCHEMBL6695893 | 0.68 | CRBN (0.50) | CRBNDDB1 | |
| SCHEMBL19585667 | 0.66 | CRBN (0.58) | CRBNDDB1 | |
| SCHEMBL9333135 | 0.66 | KDM4E (0.59) | — | |
| SCHEMBL9333117 | 0.66 | KDM4E (0.59) | — | |
| SCHEMBL9333125 | 0.66 | KDM4E (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048859-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GRUENENTHAL GMBH (DE) | 2004-03-11 | — | — | US | disclosed |
| US-6656937-B2 | Immunology moderators; interleukin antagonist; anticancer agents | GRUENENTHAL, GMBH (DE) | 2003-12-02 | — | — | US | disclosed |
| US-20030064987-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GRUENENTHAL GMBH | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048859-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GCDH, IL4I1, IL2 | CRBN 949/4885DDB1 2435/4885 |
| US-20030064987-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GCDH, IL4I1, IL2 | CRBN 949/4885DDB1 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.